BIOLOGICAL AND CLINICAL EFFECTS OF PLATELET-RICH GROWTH FACTOR PLASMA IN THE ARTHROSCOPIC TREATMENT OF OSTEOCHONDRAL LESIONS OF THE KNEE JOINT
Abstract
An osteochondral lesion is a pathological condition affecting the articular cartilage and subchondral bone. Due to the limited regenerative potential of articular cartilage, these lesions often lead to chronic pain, functional limitation, and progression to degenerative changes in the knee joint. The addition of biological adjuvants such as platelet-rich growth factor plasma aims to improve tissue regeneration and clinical outcomes. PRGF contains high concentrations of biologically active molecules such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1), which stimulate cellular proliferation, angiogenesis, and extracellular matrix synthesis. The aim of this study is to evaluate the effectiveness of platelet-rich growth factor plasma (PRGF) as a biological adjuvant in the arthroscopic treatment of osteochondral lesions of the knee by comparing clinical and radiological outcomes in patients treated with microfracture and PRGF versus patients treated with arthroscopic microfracture alone. A total of 48 patients were included and divided into two groups. The treatment in the first group consisted of arthroscopic microfracture, whereas the second group received arthroscopic microfracture combined with intra-articular application of PRGF. Objectively, the patients were followed by MRI, which was evaluated using the MOCART score. Subjectively, pain intensity and knee joint function were assessed using the VAS, IKDC, and Lysholm Score. Structural and morphological cartilage healing evaluated by MRI is associated with reduced pain and improved knee joint function.
Keywords: arthroscopic microfracture, PRGF, osteochondral lesion, VAS, IKDC.
References
2. Brittberg M. Treatment of knee cartilage lesions in 2024: From hyaluronic acid to regenerative medicine. Journal of Experimental Orthopaedics. 2024;11(2):e12016. doi:10.1002/jeo2.12016. PMID:38572391.
3. Figueroa D, Espregueira-Mendes J, Dallo I, Seil R. Age-related surgical management of chondral and osteochondral lesions. Journal of Cartilage & Joint Preservation. 2024;4(2):100172. doi:10.1016/j.jcjp.2024.100172.
4. Migliorini F, Eschweiler J, Schenker H, Baroncini A, Tingart M, Maffulli N, et al. Surgical management of focal chondral defects of the knee: a Bayesian network meta-analysis. Journal of Orthopaedic Surgery and Research. 2021;16:543. doi:10.1186/s13018-021-02684-z.
5. Valisena S, Azogui B, Nizard RS, Tscholl PM, Cavaignac E, Bouché PA, Hannouche D. Microfractures, autologous matrix-induced chondrogenesis, osteochondral autograft transplantation and autologous chondrocyte implantation for knee chondral defects: a systematic review and network meta-analysis of randomized controlled trials. EFORT Open Reviews. 2024;9(8):785–795. doi:10.1530/EOR-23-0089.
6. Mithoefer K, McAdams T, Williams RJ III, Kreuz PC, Mandelbaum BR. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. American Journal of Sports Medicine. 2009;37(10):2053–2063.
7. Steadman JR, Rodkey WG, Rodrigo JJ. Microfracture: surgical technique and rehabilitation to treat chondral defects. Clinical Orthopaedics and Related Research. 2001;(391 Suppl):S362–S369.
8. Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. Arthroscopy. 2003;19(5):477–484.
9. Van Tuijn IM, Emanuel KS, van Hugten PPW, Jeuken R, Emans PJ. Prognostic Factors for the Clinical Outcome after Microfracture Treatment of Chondral and Osteochondral Defects in the Knee Joint: A Systematic Review. Cartilage. 2023;14(1). doi:10.1177/19476035221147680.
10. Filardo G, Kon E, Di Matteo B, Di Martino A, Merli ML, Cenacchi A, et al. Platelet-rich plasma for the treatment of cartilage pathology. Open Orthopaedics Journal. 2013;7:120–128.
11. Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28(31):4551–4560.
12. Kon E, Mandelbaum B, Buda R, Filardo G, Delcogliano M, Timoncini A, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology. Arthroscopy. 2011;27(11):1490–1501.
13. Sánchez M, Anitua E, Azofra J, Aguirre JJ, Andía I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee osteoarthritis. Clinical and Experimental Rheumatology. 2008;26(5):910–913.